Filter
Reset all

Subjects

Content Types

Countries

AID systems

API

Data access

Data access restrictions

Database access

Database access restrictions

Database licenses

Data licenses

Data upload

Data upload restrictions

Enhanced publication

Institution responsibility type

Institution type

Keywords

Metadata standards

PID systems

Provider types

Quality management

Repository languages

Software

Repository types

Versioning

  • * at the end of a keyword allows wildcard searches
  • " quotes can be used for searching phrases
  • + represents an AND search (default)
  • | represents an OR search
  • - represents a NOT operation
  • ( and ) implies priority
  • ~N after a word specifies the desired edit distance (fuzziness)
  • ~N after a phrase specifies the desired slop amount
  • 1 (current)
Found 16 result(s)
Country
VirHostNet is a bioinformatic information system dedidacted to the biocuration, data integration, reproducible systems-level analysis and visualisation of Virus / Host protein-protein interactions Network based on graph theory. VirHostNet is an open and gold standard knowledgebase shared in PSI MITAB 2.5 format using the PSICQUIC webservice and distributed through the NDEx platform. VirHostNet is FAIR and is recognized as a COVID-19 ressource by Elixir bio.tools, the European Virus Bioinformatics Center and FAIRsharing.org.
COViMS (COVID-19 Infections in MS & Related Diseases) is a joint effort of the National MS Society, Consortium of MS Centers and Multiple Sclerosis Society of Canada to capture information on outcomes of people with MS and other CNS demyelinating diseases (Neuromyelitis Optica, or MOG antibody disease) who have developed COVID-19.
>>>!!!<<<2019-02-19: The repository is no longer available>>>!!!<<< >>>!!!<<<Data is archived at ChemSpider https://www.chemspider.com/Search.aspx?dsn=UsefulChem and https://www.chemspider.com/Search.aspx?dsn=Usefulchem Group Bradley Lab >>>!!!<<< see more information at the Standards tab at 'Remarks'
<<<!!!<<< This repository is no longer available. >>>!!!>>> Migration of the data, tools, and services from IRD and ViPR to BV-BRC is complete! We are now in the sunsetting phase of the transition. Starting on October 31, 2022, launching the IRD or ViPR home pages will redirect you to the new BV-BRC home page. The current plan is to completely shut down IRD and ViPR by the end of this calendar year. Although it will still be possible to use those sites until shutdown, we strongly encourage you to start using BV-BRC now.
<<<!!!<<< Effective May 2024, NCBI's Genome resource will no longer be available. NCBI Genome data can now be found on the NCBI Datasets taxonomy pages. https://www.re3data.org/repository/r3d100014298 >>>!!!>>> The Genome database contains annotations and analysis of eukaryotic and prokaryotic genomes, as well as tools that allow users to compare genomes and gene sequences from humans, microbes, plants, viruses and organelles. Users can browse by organism, and view genome maps and protein clusters.
The Coronavirus Antiviral Research Database is designed to expedite the development of SARS-CoV-2 antiviral therapy. It will benefit global coronavirus drug development efforts by (1) promoting uniform reporting of experimental results to facilitate comparisons between different candidate antiviral compounds; (2) identifying gaps in coronavirus antiviral drug development research; (3) helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development; (4) providing an objective, evidenced-based, source of information for the public; and (5) creating a hub for the exchange of ideas among coronavirus researchers whose feedback is sought and welcomed. By comprehensively reviewing all published laboratory, animal model, and clinical data on potential coronavirus therapies, the Database makes it unlikely that promising treatment approaches will be overlooked. In addition, by making it possible to compare the underlying data associated with competing treatment strategies, stakeholders will be better positioned to prioritize the most promising anti-coronavirus compounds for further development.
Country
The Biobanque québécoise de la COVID-19 (BQC19) is a pan-provincial initiative that collects, stores and shares data and blood samples from COVID-19 patients, both severe and non-severe cases and control cases, in an effort to respond effectively to the public health challenges posed by the pandemic. BQC19 believes that better understanding the disease will help society in returning to social activities and in preparing for future pandemics. It sees access to high-quality samples and data as essential in fulfilling research and works to bring about national and international research collaborations.
Country
InTOR is the institutional digital repository of the Institute of Virology, Vaccines and Sera “Torlak”. It provides open access to publications and other research outputs resulting from the projects implemented by the Institute of Virology, Vaccines and Sera “Torlak”. The software platform of the repository is adapted to the modern standards applied in the dissemination of scientific publications and is compatible with international infrastructure in this field.
Country
From April 2020 to March 2023, the Covid-19 Immunity Task Force (CITF) supported 120 studies to generate knowledge about immunity to SARS-CoV-2. The subjects addressed by these studies include the extent of SARS-CoV-2 infection in Canada, the nature of immunity, vaccine effectiveness and safety, and the need for booster shots among different communities and priority populations in Canada. The CITF Databank was developed to further enhance the impact of CITF funded studies by allowing additional research using the data collected from CITF-supported studies. The CITF Databank centralizes and harmonizes individual-level data from CITF-funded studies that have met all ethical requirements to deposit data in the CITF Databank and have completed a data sharing agreement. The CITF Databank is an internationally unique resource for sharing epidemiological and laboratory data from studies about SARS-CoV-2 immunity in different populations. The types of research that are possible with data from the CITF Databank include observational epidemiological studies, mathematical modelling research, and comparative evaluation of surveillance and laboratory methods.
In response to emerging pathogens, LabKey launched the Open Research Portal in 2016 to help facilitate collaborative research. It was initially created as a platform for investigators to make Zika research data, commentary and results publicly available in real-time. It now includes other viruses like SARS-CoV-2 where there is a compelling need for real-time data sharing. Projects are freely available to researchers. If you are interested in sharing real-time data through the portal, please contact LabKey to get started.
Research Collaborators & Institutions related to Coronavirus Epidemic Aim: Identify potential research experts or collaborators in areas related to the coronavirus epidemic across basic science, translational research, or clinical practice. Scope: A selection of Researchers active or cited in the area of Coronavirus, Middle East Respiratory Syndrome (MERS), SARS, etc.
ViralZone is a SIB Swiss Institute of Bioinformatics web-resource for all viral genus and families, providing general molecular and epidemiological information, along with virion and genome figures. Each virus or family page gives an easy access to UniProtKB/Swiss-Prot viral protein entries.